Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...
STAT22h
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...
Biogen continues dealmaking buzz with Stoke Therapeutics
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...
BioPharma Dive19h
Biogen buys rights to Stoke’s rare epilepsy drug
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
STAT22h
Biogen partners with Stoke Therapeutics on drug for severe epilepsy
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally
Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...
FierceBiotech23h
Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug
Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the ...
BioSpace57m
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...